Awards Nomination 20+ Million Readerbase
PMC/PubMed Indexed Articles

Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation

MEFA (multiepitope fusion antigen)-Novel Technology for Structural Vaccinology, Proof from Computational and Empirical Immunogenicity Characterization of an Enterotoxigenic Escherichia coli (ETEC) Adhesin MEFA

View More »

Google Scholar citation report
Citations : 2051

Journal of Vaccines & Vaccination received 2051 citations as per Google Scholar report

Flyer image
Journal of Vaccines & Vaccination peer review process verified at publons
Flyer image
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
View More
Useful Links
Share This Page
Open Access Journals
View More
Strengthening pipeline development through innovative licensing collaborations
2nd International Conference on Vaccines and Vaccination
August 20-22, 2012 Hilton Chicago/Northbrook, USA

Gavin Zealey

Scientific Tracks Abstracts: J Vaccines Vaccin

Abstract:

C ollaborations, partnerships and licenses to new products and technologies are core to the Sanofi pasteur vaccine pipeline. There are many possible deal structures (acquisitions/options/licenses\fee-for-service) to accommodate the needs of a variety of partners. Critical issues for the establishment and success of partnerships will be described to strengthen pipelines through innovative licensing

Biography :

Dr Gavin Zealey is Senior Director, Corporate Development at Sanofi pasteur. Sanofi pasteur is the vaccines business of the pharmaceutical company Sanofi and is a world leader in human vaccines. Dr Zealey identifies opportunities for global licensing and acquisition of technologies used in the development of new products. He provides strategic and tactical evaluation of new business opportunities for vaccine product development, business partnerships, their technologies and alternatives to commercial relationships. He has negotiated many agreements, creating and managing commercial relationships. He has a Ph.D. an MBA from the Kellogg School of Management, is registered to practice before the Canadian and US Patent Offices and is a Certified Licensing Professional

PDF HTML